ARX 788
Alternative Names: Antibody-drug conjugate - Ambrx/Zhejiang Medicine; ARX-788; JNJ-0683; NCB-001Latest Information Update: 06 Sep 2024
At a glance
- Originator Ambrx
- Developer Ambrx; NovoCodex Biopharmaceuticals
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies; Small molecules
- Mechanism of Action Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II/III HER2 positive breast cancer
- Suspended Breast cancer; Gastric cancer; Solid tumours
Most Recent Events
- 29 Aug 2024 Fudan University plans a phase II trial for Breast cancer (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in September 2024 (IV) (NCT06578286)
- 31 May 2024 Efficacy data form phase II I-SPY trial in Breast cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 31 May 2024 Interim efficacy and adverse events data from the phase II/III ACE-Breast-02 trial in HER2 positive breast-cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)